Ibopamine vs. digoxin in chronic heart failure: a double-blind, crossover study

Area of Science:

• Cardiology
• Pharmacology

Background:

• Chronic heart failure (CHF) significantly impacts cardiac function and exercise capacity.
• Dopamine derivatives offer potential therapeutic options for managing heart failure.
• Digoxin is a standard treatment, but alternatives are sought.

Purpose of the Study:

• To evaluate the inotropic effect of ibopamine in patients with chronic heart failure.
• To compare the efficacy of ibopamine with digoxin in improving cardiac response to exercise.
• To assess safety and side effects of ibopamine versus digoxin.

Main Methods:

• A double-blind, randomized crossover study involving 10 patients with chronic heart failure (NYHA II-III) in sinus rhythm.
• Patients received ibopamine (100 mg t.i.d.) or digoxin (0.25 mg o.d.) for 10 days each, separated by 5-day washout periods.
• Cardiac response was assessed via static (hand grip) and dynamic (bicycle ergometer) exercise tests, measuring PEP/LVET and O2 consumption.

Main Results:

• Both ibopamine and digoxin significantly improved cardiac response to exercise compared to placebo/washout periods.
• Key indicators like pre-ejection period/left ventricular ejection time (PEP/LVET) decreased significantly (p < 0.001) with both drugs.
• Oxygen consumption (O2 consumption) improved similarly for both ibopamine and digoxin during exercise.

Conclusions:

• Ibopamine demonstrates comparable efficacy to digoxin in enhancing cardiac function and exercise tolerance in heart failure patients with sinus rhythm over a 10-day treatment period.
• Ibopamine represents a potential alternative to digoxin for managing heart failure in this patient population.
• Further research is necessary to ascertain the long-term effectiveness and safety profile of ibopamine.